125-LB: Individualized Cost-Effectiveness Assessment of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Sulfonylureas as Add-On Therapy in People with Inadequately Controlled Type 2 Diabetes (T2D) Under Metformin Monotherapy
Year: 2022
Type: article
Source: Diabetes
DOI: 10.2337/db22-125-lb
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281721671